Key consensus points established specific age-based recontact practices for high penetrance CSGs, BRCA1, BRCA2 and PALB2, including recontact at 25 years to review breast cancer risk management and ovarian cancer risk management at gene-specific ages. This evidence concerns the gene BRCA2 and ovarian cancer.